There are ethical and legal restrictions (i.e., data contains potentially sensitive information and personally identifiable information) since the data contains sensitive patient information. However, the data is available from NHIS (National Health Insurance System) upon request to the 'Information analysis department in Big data operation room'. Researchers who may wish to get access to the data could contact the Bid data operation room (+82-33-736-2432). Also, the url for the website is: <https://nhiss.nhis.or.kr/bd/ab/bdaba000eng.do;jsessionid=cK18Qv01aQU6z3lIVw344vo> AFGSXalRxAdKkU8XvPL1E2XK9y0CdK1BRwzPwbhzQ.primrose2_servlet_engine1 Future researchers who wish to get access to the data we have utilized could request the 2006-2016 claims data of those with schizophrenia (F20, ICD-10 code).

Introduction {#sec001}
============

Many individuals have mental disorders globally, and one in four people will develop a mental disorder during their lifetime \[[@pone.0235736.ref001]\]. Specifically, the lifetime and 12-month prevalence rate of having any psychiatric disorder in South Korea (Korea from hereon) is 25.4% and 11.9%, respectively \[[@pone.0235736.ref002]\]. Moreover, the global burden of mental disorders comprises about 30% of years lived with disability and 15% of disability-adjusted life years \[[@pone.0235736.ref003]\]. These numbers indicate that improving mental health is a major aspect of increasing one's wellbeing.

Schizophrenia is a psychiatric disorder that includes symptoms such as delusions, hallucinations, and disorganized speech and behavior \[[@pone.0235736.ref004]\]. According to a systematic literature review \[[@pone.0235736.ref005]\], the median 12-month and lifetime prevalence rate of schizophrenia is 0.33% (interquartile range = 0.26%--0.51%) and 0.48% (interquartile range = 0.34--0.85%), respectively. Despite the low prevalence rate, schizophrenia has detrimental effects on patients' lives, and it places tremendous health, social, and economic burdens on patients, families, caregivers, and society \[[@pone.0235736.ref006]\]. For instance, patients with schizophrenia have low quality of life \[[@pone.0235736.ref007]\], impeded employment \[[@pone.0235736.ref008]\], can be involved in violence \[[@pone.0235736.ref009]\], have a high risk of acquiring physical diseases (e.g., cardiovascular disease) \[[@pone.0235736.ref010]\], and have a reduced life expectancy \[[@pone.0235736.ref011]\]. Consequently, it is no surprise that schizophrenia is in the top 15 (of 328) of diseases and injuries included in the "leading cause of years lived with disability" \[[@pone.0235736.ref012]\].

Notably, the Korean government has increased the national health expenditures allocated to mental health \[[@pone.0235736.ref013]\]. Despite the increase, only 2.6% of the total expenditures was allocated to mental health in 2014 \[[@pone.0235736.ref014]\]. Moreover, the amount is only about 2% of what the U.S. allocates to mental health \[[@pone.0235736.ref015]\]. Accordingly, it is important to determine what area requires more funding.

Korea provides universal healthcare through National Health Insurance (NHI) and Medical Aid programs. The NHI covers about 97% of the population and the rest is covered by Medical Aid \[[@pone.0235736.ref016]\]. Consequently, it is possible to construct a health insurance database that contains key data such as health records, prescriptions, etc. Moreover, the NHI Service (NHIS) provide these data to researchers for research purposes.

Investigating the cost-of-illness (COI) of schizophrenia is needed to establish proper and effective healthcare policy and intervention \[[@pone.0235736.ref017]\]. However, scant studies have investigated the economic burden of schizophrenia in Korea. A previous study \[[@pone.0235736.ref018]\] regarding the economic burden of schizophrenia (estimated from a societal perspective) in Korea is dated, and other studies \[[@pone.0235736.ref019],[@pone.0235736.ref020]\] utilized disability-adjusted life years when estimating the economic cost. Moreover, no study has investigated the economic burden trend regarding schizophrenia in Korea. Therefore, from a societal perspective, we examined the COI trend of schizophrenia in Korea from 2006 to 2016.

Materials and methods {#sec002}
=====================

Study design {#sec003}
------------

COI studies estimate the direct and indirect costs intertwined with a specific disease \[[@pone.0235736.ref016]\]. Direct costs are disease-related payments, which are divided into two parts: direct healthcare costs and direct non-healthcare costs. Indirect costs account for resources that are lost owing to the disease. Therefore, we calculated the cost for three main categories: direct healthcare costs, direct non-healthcare costs, and indirect costs related to those being treated for schizophrenia in Korea. When converting Korean Won to U.S. dollars, we used the average exchange rate of each year. The prevalence approach was utilized for direct costs, and the human capital approach was used for indirect costs.

The requirement for written, informed consent was waived. This study was approved by the institutional review board of the National Center for Mental Health, Korea (no. 116271-2017-10).

We utilized the following sources: 1) claims data and a medical expense survey from the NHIS \[[@pone.0235736.ref021]\]; 2) Korean Statistical Information Service, Statistics Korea \[[@pone.0235736.ref022]\]; 3) the National Survey of Persons with Disabilities \[[@pone.0235736.ref023],[@pone.0235736.ref024]\]; 4) Budget and Fund Operation Plan, Ministry of Justice \[[@pone.0235736.ref025]\]; 5) Budget and Fund Operation Plan, Ministry of Health and Welfare \[[@pone.0235736.ref026]\]; and 6) annual reports of the National Mental Health Welfare Commission \[[@pone.0235736.ref027]\].

Direct healthcare costs {#sec004}
-----------------------

Direct healthcare costs are defined as medical care costs, which include inpatient care costs, outpatient treatment costs, pharmacy costs, and non-covered care costs. The information regarding inpatient treatment costs, outpatient treatment costs, and pharmacy costs were obtained from the NHIS claims data from 2006 to 2016 \[[@pone.0235736.ref021]\]. However, the non-covered medical expenses were not retrievable from NHIS; therefore, these were estimated by the proportion of the non-covered care costs (i.e., 4.3% for inpatient and 2.3% for outpatient care) regarding mental health from the 2009 medical expense survey \[[@pone.0235736.ref028]\].

Direct non-healthcare costs {#sec005}
---------------------------

Direct non-healthcare costs are defined as costs that are associated with patient management, other than direct healthcare costs. We included the following direct non-healthcare costs in this study: incarceration costs, community mental healthcare center costs, sanatoria costs, rehabilitation facility costs, and transport costs \[[@pone.0235736.ref002]\]. Patients with schizophrenia are involved in crime (mediated by substance use comorbidity) (mediated by substance use comorbidity) more so than is the general population \[[@pone.0235736.ref009]\]. Accordingly, there are various costs that are related to this issue such as policing and prosecution costs. However, those specific data were not available. Instead, we focused on costs that are retrievable---incarceration cost. Incarceration cost was calculated based on the Budget and Fund Operation Plan, Ministry of Justice \[[@pone.0235736.ref025]\]. Patients do not receive a diagnosis or prescription at a community mental health center; rather, patients visit community mental healthcare centers for rehabilitation purposes. In addition, most community mental healthcare costs are covered by the government, not by the individual. Therefore, community mental healthcare center costs were considered as direct non-healthcare costs.

Community mental healthcare center costs were estimated using information included in the budget of the local mental health centers \[[@pone.0235736.ref027]\]. The cost for sanatoria was based on the Budget and Fund Operation Plan, Ministry of Health and Welfare \[[@pone.0235736.ref026]\]. Psychiatric rehabilitation is vital for treatment as it assists patients with reaching their optimal level of functioning \[[@pone.0235736.ref029]\]. Therefore, the costs for rehabilitation facilities were also estimated through the Budget and Fund Operation Plan, Ministry of Health and Welfare \[[@pone.0235736.ref026]\]. The community mental healthcare center costs, sanatoria costs, and psychiatric rehabilitation costs were estimated by the annual operating costs from each report (e.g., annual operating cost of community mental healthcare center by local mental health centers in 2007 \* treated prevalence rate of schizophrenia in 2007). We estimated the transport cost by multiplying the total number of hospital visits by the mean return fare \[[@pone.0235736.ref018]\].

Indirect costs {#sec006}
--------------

Indirect costs included productivity loss due to unemployment, workplace productivity loss due to morbidity, premature death costs, and caregiving costs. Information regarding indirect costs was retrieved from Statistics Korea \[[@pone.0235736.ref022]\], the NHIS \[[@pone.0235736.ref021]\], and the National Survey of Persons with Disabilities \[[@pone.0235736.ref023],[@pone.0235736.ref024]\]. There has been a shift with caregiving responsibility of those with mental disorders---from hospital-based to family- or caregiver-based \[[@pone.0235736.ref030]\]. Therefore, it is important to estimate the caregiving costs associated with schizophrenia. The information regarding caregiving costs was estimated by information provided by Statistics Korea \[[@pone.0235736.ref022]\], the National Survey of Persons with Disabilities \[[@pone.0235736.ref023],[@pone.0235736.ref024]\], and the NHIS \[[@pone.0235736.ref021]\]. For the exact equations for indirect costs, see [S1 Table](#pone.0235736.s001){ref-type="supplementary-material"}.

Sensitivity analyses {#sec007}
--------------------

Some costs were not attributable directly (e.g., non-covered medical expenses). Therefore, we conducted a sensitivity analysis to evaluate the robustness of the estimated costs utilizing the lowest (11%) and highest (20%) proportion of non-covered medical expenses reported by NHIS \[[@pone.0235736.ref031]\]. In addition, the discount rates (0% and 5%) of expected future earnings and the productivity costs due to premature mortality (using the friction-cost method for 1 month, 3 months, and 6 months) were calculated. A more-detailed description of the method regarding sensitivity analyses can be found elsewhere \[[@pone.0235736.ref018]\]. All statistical analyses were performed with SAS 9.4 (SAS Institute Inc., Cary, North Carolina, USA).

Results {#sec008}
=======

Treated prevalence of schizophrenia in Korea from 2006 to 2016 {#sec009}
--------------------------------------------------------------

The numbers of patients who were treated for schizophrenia, those registered as having a mental disability, and those who died from schizophrenia (i.e., cause of death was schizophrenia) or committed suicide each year from 2006 to 2016 are presented in [Table 1](#pone.0235736.t001){ref-type="table"}. The treated prevalence rate has increased from 0.33% to 0.40% during this period. In total, 448,490 patients (when duplicates were removed) were treated for schizophrenia from 2006 to 2016 in Korea. Additionally, 109,306 individuals (when duplicates were removed) were classified as having mental disability among those treated for schizophrenia during that period. Moreover, about 1,000 people each year died from schizophrenia or committed suicide.

10.1371/journal.pone.0235736.t001

###### Individuals treated for schizophrenia, registered as having a mental disability, or who died from schizophrenia/committed suicide from 2006 to 2016 in Korea.

![](pone.0235736.t001){#pone.0235736.t001g}

         Treated for schizophrenia   Determined to have a mental disability   Died from schizophrenia or suicide                  
  ------ --------------------------- ---------------------------------------- ------------------------------------ ------ ------- ------
  2006   160,157                     0.33                                     32,300                               0.20   631     0.00
  2007   165,544                     0.34                                     48,536                               0.29   926     0.01
  2008   171,663                     0.35                                     58,168                               0.34   1,008   0.01
  2009   175,230                     0.35                                     64,824                               0.37   1,054   0.01
  2010   174,492                     0.35                                     69,468                               0.40   1,066   0.01
  2011   179,254                     0.36                                     73,664                               0.41   1,122   0.01
  2012   187,390                     0.37                                     76,548                               0.41   1,091   0.01
  2013   189,961                     0.38                                     78,260                               0.41   1,093   0.01
  2014   191,502                     0.38                                     79,694                               0.42   1,063   0.01
  2015   199,743                     0.39                                     82,058                               0.41   1,138   0.01
  2016   202,345                     0.40                                     82,976                               0.41   1,110   0.01

COI of schizophrenia each year by each category {#sec010}
-----------------------------------------------

The total COI of schizophrenia and specific costs for each category---direct healthcare costs, direct non-healthcare costs, and indirect costs---are presented in [Table 2](#pone.0235736.t002){ref-type="table"}. The total direct healthcare cost was about 451 billion Won in 2006 and rose to approximately 868 billion Won in 2016. The direct non-healthcare cost rose from about 135 billion Won in 2006 to 244 billion Won in 2016. The total indirect cost was 3.09 trillion Won in 2006 and increased to 5.79 trillion Won in 2016. Moreover, the direct healthcare cost, direct non-healthcare cost, and indirect cost accounted for about 12--14%, 3--4%, and 83--85% of the total COI of schizophrenia during this period, respectively.

10.1371/journal.pone.0235736.t002

###### Overall cost of schizophrenia in Korea from 2006 to 2016.

![](pone.0235736.t002){#pone.0235736.t002g}

  Cost type                                 2006                    \%                         2007            \%        2008            \%        2009            \%        2010            \%        2011            \%        2012            \%        2013            \%        2014            \%        2015            \%        2016            \%                    
  ----------------------------------------- ----------------------- -------------------------- --------------- --------- --------------- --------- --------------- --------- --------------- --------- --------------- --------- --------------- --------- --------------- --------- --------------- --------- --------------- --------- --------------- --------- ----------- -----
  **Direct cost**                           **Direct healthcare**   **Inpatient care costs**   325,324         75%       361,527         75%       399,306         76%       486,348         78%       528,291         78%       567,542         79%       598,032         80%       619,228         80%       633,385         81%       660,052         81%       674,963     81%
  **uncovered inpatient care cost**         13,289                  14,646                     15,926          20,033    21,977          23,617    24,829          25,743    26,334          27,375    27,950                                                                                                                                                                  
  **Outpatient care costs**                 93,095                  21%                        101,722         21%       109,056         20%       118,553         19%       125,385         18%       128,384         18%       126,982         17%       132,692         17%       134,319         17%       136,327         16%       140,672         17%                   
  **uncovered outpatient care cost**        1,825                   1,994                      2,148           2,425     2,605           2,674     2,629           2,741     2,779           2,805     2,887                                                                                                                                                                   
  **Pharmacy costs**                        17,583                  4%                         19,807          4%        21,677          4%        23,075          4%        23,831          3%        23,895          3%        23,845          3%        23,535          3%        21,955          3%        22,078          3%        22,221          3%                    
  **Total**                                 **451,116**             **12%**                    **499,695**     **12%**   **548,114**     **12%**   **650,434**     **13%**   **702,089**     **14%**   **746,111**     **14%**   **776,316**     **13%**   **803,939**     **13%**   **818,772**     **13%**   **848,637**     **13%**   **868,693**     **13%**               
  **Direct non-healthcare**                 **Incarceration**       1,223                      1%              1,261     1%              1,540     1%              1,545     1%              1,901     1%              1,813     1%              2,023     1%              2,530     1%              2,673     1%              3,471     1%              3,969     2%          
  **Community mental healthcare centers**   4,149                   3%                         3,966           3%        4,347           3%        4,738           3%        4,657           3%        5,033           3%        5,357           3%        6,065           3%        6,537           3%        17,113          7%        16,902          7%                    
  **Sanatoria**                             81,443                  60%                        84,847          60%       86,254          59%       89,653          59%       92,319          59%       95,507          59%       129,532         63%       115,482         57%       118,509         56%       122,238         52%       126,006         52%                   
  **Rehabilitation facilities**             40,580                  30%                        41,835          30%       43,129          29%       44,463          29%       45,838          29%       47,256          29%       54,136          26%       61,310          30%       67,380          32%       76,888          33%       80,116          33%                   
  **Transport costs**                       8,028                   6%                         9,541           7%        11,153          8%        11,738          8%        12,262          8%        13,281          8%        14,971          7%        15,636          8%        16,061          8%        16,692          7%        17,055          7%                    
  **Total**                                 **135,423**             **4%**                     **141,450**     **3%**    **146,424**     **3%**    **152,137**     **3%**    **156,977**     **3%**    **162,891**     **3%**    **206,019**     **4%**    **201,023**     **3%**    **211,160**     **3%**    **236,402**     **4%**    **244,048**     **4%**                
  **Direct cost total**                     **586,539**             **16%**                    **641,145**     **15%**   **694,537**     **15%**   **802,572**     **17%**   **859,066**     **17%**   **909,002**     **17%**   **982,335**     **17%**   **1,004,962**   **16%**   **1,029,932**   **16%**   **1,085,039**   **16%**   **1,112,741**   **16%**               
  **Indirect Cost**                         **　**                  **Unemployment**           2,100,191       68%       2,276,720       63%       2,491,115       62%       2,493,093       62%       2,569,126       62%       2,912,681       64%       3,104,954       64%       3,288,018       64%       3,516,994       65%       3,658,302       65%       3,773,508   65%
  **Reduced productivity at work**          455,272                 15%                        491,123         14%       537,121         13%       546,017         14%       558,917         13%       524,470         11%       559,134         12%       623,497         12%       622,725         12%       650,899         12%       674,513         12%                   
  **Premature mortality**                   335,560                 11%                        510,854         14%       582,374         15%       593,426         15%       585,936         14%       634,954         14%       621,983         13%       659,451         13%       637,711         12%       684,832         12%       682,256         12%                   
  **Caregiver productivity loss**           202,672                 7%                         315,775         9%        396,035         10%       410,914         10%       446,588         11%       505,304         11%       546,587         11%       583,560         11%       614,523         11%       637,921         11%       663,570         11%                   
  **Indirect cost total**                   **3,093,695**           **84%**                    **3,594,472**   **85%**   **4,006,646**   **85%**   **4,043,449**   **83%**   **4,160,567**   **83%**   **4,577,408**   **83%**   **4,832,658**   **83%**   **5,154,527**   **84%**   **5,391,954**   **84%**   **5,631,954**   **84%**   **5,793,848**   **84%**               
  **Total cost**                            **3,680,234**           **　**                     **4,235,617**   **　**    **4,701,183**   **　**    **4,846,021**   **　**    **5,019,633**   **　**    **5,486,410**   **　**    **5,814,993**   **　**    **6,159,489**   **　**    **6,421,886**   **　**    **6,716,993**   **　**    **6,906,589**   **　**                

Total direct and indirect cost of schizophrenia per sex and age group {#sec011}
---------------------------------------------------------------------

[Fig 1](#pone.0235736.g001){ref-type="fig"} displays the direct and indirect cost trend of different age groups per sex. The direct healthcare costs of those in their 40s and 50s (both men and women) showed the highest proportion among different age groups. Especially, the direct cost attributable to those in their 50s was the highest among the different age groups since 2014 for men and since 2012 for women. Moreover, individuals who were younger than 20 years and those in their 20s had a much lower proportion of cost compared to those in their 30s, 40s, and 50s.

![Direct and indirect cost of men and women by different age groups.](pone.0235736.g001){#pone.0235736.g001}

The indirect cost for all age groups showed a similar pattern for men and women. However, costs attributable to men were higher than among women---especially those in their 40s and 50s. The highest indirect cost was attributable to those in their 40s for both men and women.

Trend of indirect cost of men and women for each category {#sec012}
---------------------------------------------------------

[Fig 2](#pone.0235736.g002){ref-type="fig"} shows the trend of indirect cost for men and women per the three cost categories. For both men and women, most of the cost was due to unemployment (about 65% each year). Men showed much higher economic cost due to unemployment than did women. For example, cost due to unemployment for men in 2016 was about 2.42 trillion Won; however, for women, it was 1.35 trillion Won.

![Indirect cost of men and women by specific costs.](pone.0235736.g002){#pone.0235736.g002}

COI trend of schizophrenia in Korea from 2006 to 2016 {#sec013}
-----------------------------------------------------

The COI of treated schizophrenia in South Korea from 2006 to 2016 is presented in [Fig 3](#pone.0235736.g003){ref-type="fig"}. The COI of schizophrenia in Korea was 3.68 trillion Won in 2006 and 6.90 trillion Won in 2016, showing a steady increase. Compared to 2006, the treated prevalence and the socioeconomic cost of schizophrenia increased by 1.26-fold and 1.88-fold, respectively (whereas Korea's gross domestic product has increased by 1.70-fold) \[[@pone.0235736.ref032]\]. The COI of schizophrenia in 2016 was 0.42% of Korea's total gross domestic product.

![Economic burden of schizophrenia in Korea from 2006--2016.](pone.0235736.g003){#pone.0235736.g003}

Sensitivity analysis {#sec014}
--------------------

The base case COI estimates and the sensitivity analysis results from 2006 to 2016 are shown in [Table 3](#pone.0235736.t003){ref-type="table"}. The COI in 2016 was 6.97 and 7.06 trillion Won when non-covered payments were estimated to be 11% and 20%, respectively. When 0% and 5% discount rates were utilized, the COI of schizophrenia increased to 7.27 trillion Won and decreased to 6.77 trillion Won, respectively.

10.1371/journal.pone.0235736.t003

###### Sensitivity analysis on key burden of illness assumptions.
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  Assumption                               Cost                                                                                                                                                                                                                        
  ---------------------------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- -------------------
  Base case                                                    3,680,233,795,244   4,235,617,109,128   4,701,182,922,976   4,846,020,781,817   5,019,633,100,110   5,486,410,086,705   5,814,992,976,769   6,159,488,759,051   6,421,885,598,523   6,716,992,852,444   6,906,588,614,709
  Self-payment cost due to exclusion       11%                 3,711,257,139,215   4,269,731,656,007   4,738,196,072,152   4,891,400,747,236   5,069,180,707,246   5,539,122,026,917   5,869,633,553,680   6,216,208,548,882   6,479,799,073,198   6,776,839,043,580   6,967,790,505,589
  20%                                      3,758,443,405,139   4,321,639,376,898   4,794,535,810,751   4,960,780,852,854   5,144,995,017,811   5,619,920,613,540   5,953,597,774,746   6,303,349,096,437   6,568,803,055,861   6,868,910,792,248   7,061,921,021,206   
  Discount rate                            0%                  3,874,440,653,050   4,536,378,779,999   5,036,764,090,884   5,184,696,012,249   5,348,497,726,623   5,841,530,537,553   6,156,700,946,741   6,518,794,425,616   6,763,938,237,563   7,097,991,969,143   7,265,716,631,374
  5%                                       3,608,316,562,974   4,124,713,574,902   4,576,781,509,309   4,719,882,859,041   4,896,913,092,329   5,353,699,002,535   5,686,672,763,369   6,024,025,376,641   6,292,603,171,235   6,574,780,651,454   6,770,256,188,743   
  Friction period for worker replacement   1 mo.               3,346,061,583,850   3,726,839,993,401   4,121,236,220,694   4,255,075,036,749   4,436,206,798,623   4,854,178,186,053   5,195,726,556,241   5,502,927,031,116   5,787,023,551,063   6,035,133,811,143   6,227,442,843,374
  3 mo.                                    3,348,836,444,680   3,730,993,735,545   4,126,091,147,815   4,260,034,765,749   4,441,227,022,623   4,859,621,923,053   5,201,159,455,241   5,508,706,562,116   5,792,721,578,063   6,041,078,895,143   6,233,663,267,374   
  6 mo.                                    3,352,998,735,925   3,737,224,348,761   4,133,373,538,496   4,267,474,359,249   4,448,757,358,623   4,867,787,528,553   5,209,308,803,741   5,517,375,858,616   5,801,268,618,563   6,049,996,521,143   6,242,993,903,374   

mo. = month

Discussion {#sec015}
==========

From a societal perspective, we estimated the COI trend of schizophrenia in Korea from 2006 to 2016. The overall economic burden of schizophrenia has increased steadily from 2006, and the cost trend is similar to that of a previous study that utilized data from 2005 \[[@pone.0235736.ref018]\].

The increased treatment prevalence could be attributable to Korea's efforts to alleviate stigma against schizophrenia, which led some patients to actively seek help for their symptoms. The term for schizophrenia in Korean was originally "*jungshinbunyeolbyung*," which translates to "mind-split disorder." To reduce stigma, in 2012, the Korean Neuropsychiatric Association changed the term to "*johyeonbyung*," which translates to "attunement disorder." According to a Korean study \[[@pone.0235736.ref033]\], changing the term had a significant effect on reducing stigma toward schizophrenia.

Despite the increased treatment prevalence, there is much room for improvement. Among the general population, about 10% received help by a mental health professional (e.g., psychiatrists, other medical doctors, other mental health professionals, nurses, etc.) for mental health problems in Korea \[[@pone.0235736.ref002]\]. Moreover, only about 20% among those diagnosed with a mental disorder received help from a mental health professional \[[@pone.0235736.ref002]\], which is much lower than the rate observed in New Zealand (38.9%), the U.S. (43.1%), Spain (35.5%), Belgium (39.5%), and Australia (34.9%) \[[@pone.0235736.ref034]--[@pone.0235736.ref036]\]. Moreover, a previous study \[[@pone.0235736.ref037]\] emphasized the need for education on etiology and treatment regarding schizophrenia in Korea to guide patients to use mental health services. Further, sex and personality traits should be considered when providing education to promote help-seeking behavior \[[@pone.0235736.ref038]\]. Researchers and practitioners thus need to work to raise public awareness concerning schizophrenia to promote patients' help-seeking behavior.

Based on our estimation, inpatient care comprised most of the direct healthcare costs. The inpatient care cost was 75% of the direct healthcare cost in 2006, and this increased to 81% in 2016. The number of admissions into mental hospitals decreased in developed countries \[[@pone.0235736.ref039]\]; however, Korea shows an opposite trend. The numbers of psychiatric beds have continuously increased and the length of stay at a psychiatric hospital remains long (i.e., 116 days)---in fact, the longest among Organization for Economic Cooperation and Development countries \[[@pone.0235736.ref040]\]. This could be explained by the payment system in Korea. About 97% of the total population in Korea is supported by the NHIS, and the remaining 3% are supported by Medical Aid. The zero co-payment for those who receive Medical Aid may provoke those to stay longer at a psychiatric hospital. In fact, only 3% of the total population receives Medical Aid; however, about 50% and 60% of the psychiatric admissions and total long-term admissions, respectively, are by those who receive Medical Aid \[[@pone.0235736.ref041]\]. The government needs to guide these patients to receive treatment from a community-based facility rather than obtaining hospital-based treatment.

Further, the Mental Health Act could account for the high inpatient care costs. Korea has a very high rate (i.e., 80%) of involuntary admissions, which is regulated by the Mental Health Act. This high rate of involuntary admissions is higher than other countries \[[@pone.0235736.ref042]\]. According to Article XXIV of the Mental Health Act, an institution can involuntarily hospitalize a patient when a psychiatrist judges that he or she needs hospitalization \[[@pone.0235736.ref043]\]. However, a stricter regulation regarding involuntary admissions and a shorter period before being able to be discharged have been applied owing to the revised Mental Health Act in 2016 \[[@pone.0235736.ref044]\]. Based on this revision, it is expected that inpatient costs will decrease, and outpatient costs and non-healthcare costs will increase.

Of the different age groups, those in their 40s and 50s accounted for most of the direct costs. Those in their 20s and younger had much lower direct healthcare costs comparatively. The onset of schizophrenia typically occurs in late adolescence \[[@pone.0235736.ref045]\]. However, our data showed that adolescents and those in their 20s are not actively being treated for schizophrenia. In fact, Korea has a higher duration of untreated psychosis (DUP; i.e., 840 days) compared to Western countries \[[@pone.0235736.ref046]\]. This indicates that patients are not being treated during the most critical period. Since there is an association between longer DUP and worse outcomes among patients with a psychosis \[[@pone.0235736.ref047]\], researchers and policymakers need to provide ways to promote patients to seek help when they notice their first psychotic symptom. Especially, an integrated community program is needed to improve outcomes and to raise intervention efficiency \[[@pone.0235736.ref048]\].

Most direct non-healthcare costs were for sanatoria and rehabilitation facility costs, which accounts for about 90% when combined. This shows that most of the burden from schizophrenia concerns long-term care, which is consistent with previous studies \[[@pone.0235736.ref018],[@pone.0235736.ref049]\]. It seems that Korean patients miss the chance for early intervention owing to a high DUP \[[@pone.0235736.ref046]\], which leads to a poor prognosis \[[@pone.0235736.ref047]\] and patients requiring inpatient care. Incarceration accounts for about 1% of the direct non-healthcare costs. However, considering the severity of the matter, efforts to prevent violence that is associated with schizophrenia are needed. A meta-analysis \[[@pone.0235736.ref009]\] that investigated the association between schizophrenia and violence stated that substance abuse comorbidity mediates the association between schizophrenia and violence. Therefore, experts need to consider preventing substance abuse among patients with schizophrenia.

The cost due to unemployment was the highest among all indirect costs, regardless of sex. However, the cost was much higher for men, which may be attributable to the income difference between men and women in Korea \[[@pone.0235736.ref022]\]. Moreover, cost due to premature mortality was the second highest for men. This is consistent with previous research showing that men have a higher suicide completion rate than do women \[[@pone.0235736.ref050]\]. Therefore, suicide prevention interventions are required for men with schizophrenia. For women, the second highest cost among indirect costs was due to caregiver productivity loss since 2010.

Overall, the COI of schizophrenia in Korea has been steadily increasing since 2006. The Korean government has made strides concerning citizens' mental health. The most prominent change is the revised Mental Health Act in 2016 \[[@pone.0235736.ref044]\]. Through this revision, the unnecessarily long and involuntary admissions of psychiatric patients are expected to decrease. Moreover, the government, researchers, and policymakers need to focus on guiding patients to receive treatment, especially at a community-based facility. Future study is needed to determine how the COI in Korea changes owing to the revision of the Mental Health Act and other efforts the Korean government has implemented.

Despite its importance, this study had some limitations. First, we utilized the treated prevalence rate. Therefore, we did not acquire information about those who have schizophrenia but are not being treated. However, rather than using self-report data, we utilized actual claim data from the NHIS. Second, the costs, especially the indirect costs, are estimated values; the indirect costs could be underestimated or overestimated. For example, the budget for the central government was considered when estimating costs for community centers and specific proportions of budget allocated in each local government to community center were not regarded. Despite these limitations, we tried to use exact numbers when the information was retrievable. For instance, the numbers concerning those with a mental disability, suicide, and mortality were exact numbers rather than estimates.

Conclusions {#sec016}
===========

The current study estimated the COI trend of schizophrenia in South Korea from 2006 to 2016. This study was based on a societal perspective and we employed a prevalence-based approach for direct costs and a human capital approach for indirect costs. We also utilized information from various sources. The results indicated that more patients with schizophrenia are seeking help; however, there is still room for improvement. Most costs were attributed from indirect costs, and those in their 40s and 50s accounted for most of the COI of schizophrenia in Korea. Our results also imply that community-based care, instead of hospital care, is needed in Korea. Future studies need to examine how the Mental Health Act in 2016 has changed the COI of schizophrenia in Korea.

Supporting information {#sec017}
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Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Editor comments:

Before submitting the manuscript to peer review, some changes are necessary. In particular:

At the Introduction, please include a brief description of the South Korean health care system. Please, justify the classification of costs. Usually, non-healthcare direct costs include formal and informal care; why are they considered as indirect costs? Also, why community mental healthcare center costs are not considered health care costs?

Please, provide further detail about how the results are obtained (not only about data sources, but about the procedure to arrive to final figures which are shown in the manuscript). For instance, according to reference \[10\], "Schizophrenia and other psychoses are associated with violence and violent offending, particularly homicide. However, most of the excess risk appears to be mediated by substance abuse comorbidity". How do you estimate the incarceration costs due to schizophrenia? Do you assume that all the incarceration costs corresponding to schizophrenic inmates are part of non-healthcare direct costs of schizophrenia? This is only an example, more detail should be given for the rest of calculations.

The approach used to estimate indirect costs is the human capital approach, not the prevalence approach. Please, revise the Abstract, the Introduction and the Discussion sections accordingly.

We would appreciate receiving your revised manuscript by Nov 16 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>
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A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Rosa Maria Urbanos Garrido, PhD

Academic Editor
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When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2.  We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>.
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a\) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b\) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see <http://www.bmj.com/content/340/bmj.c181.long> for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>.
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We provided a brief description of the South Korean healthcare system in the Introduction as follows:

Korea provides universal healthcare through National Health Insurance (NHI) and Medical Aid program. The NHI covers about 97% of the population and the rest is covered by Medical Aid. Consequently, it is possible to construct a health insurance database that contains key data such as health records, prescriptions, etc. Moreover, the NHI Service (NHIS) provides these data to researchers for research purposes. (pg.4)

We included cost classifications as follows:

Direct costs are disease-related payments which are divided into two parts: direct healthcare costs and direct non-healthcare costs. Indirect costs account for resources that are lost owing to the disease. (pg. 4)

Direct healthcare costs are defined as medical care costs, which include inpatient care costs, outpatient treatment costs, pharmacy costs, and non-covered care costs. (pg. 5)

Direct non-healthcare costs are defined as costs that are associated with patient management, other than direct healthcare costs. (pg. 5)

Patients do not receive a diagnosis or prescription at a community mental health center; rather, patients visit community mental healthcare centers for rehabilitation purposes. In addition, most community mental healthcare costs are covered by the government, not by the individual. Therefore, community mental healthcare center costs were considered as direct non-healthcare costs. (pg. 6)

The community mental healthcare center costs, sanatoria costs, and psychiatric rehabilitation costs were estimated by the annual operating costs from each report (e.g., annual operating cost of community mental healthcare center by local mental health centers in 2007 \* treated prevalence rate of schizophrenia in 2007). We estimated the transport cost by multiplying the total number of hospital visits by the mean return fare \[17\]. (pg. 6)

For the exact equations for indirect costs, see Supporting information. (pg. 7 and pg. 26)

The cost-of-illness trend was estimated from a societal perspective using a prevalence-based approach for direct costs and a human capital approach for indirect costs. (pg. 2)

The prevalence approach was utilized for direct costs, and the human capital approach was used for indirect costs. (pg. 4)

This study was based on a societal perspective and we employed a prevalence-based approach for direct costs and a human capital approach for indirect costs. (pg. 16)

We revised the Abstract, Introduction, and the Discussion per your request.
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We greatly appreciate the academic editor and reviewer for thoroughly reviewing our manuscript. We made revisions per the comments and suggestions that were provided, which are highlighted below. We hope our responses are suitable and that the revised manuscript is now acceptable for publication in PLoS One.

Journal Requirements

1\. Please ensure that all statement are supported by adequate references, and that the references studies are critically analysed. For example, we note that your statement \"Patients with schizophrenia are involved in crime more so than is the general population\" does not seem to reflect the conclusions drawn by the study referenced ( Fazel, Seena, et al. \"Schizophrenia and violence: systematic review and meta-analysis.\" PLoS medicine 6.8) , which concluded that \"most of the excess risk appears to be mediated by substance abuse comorbidity\". Please ensure that the aspect of substance abuse comorbidity is mentioned, to provide a balanced view on the association between schizophrenia and crime prevalence, and to reflect the content of the cited study.

� Thank you for providing this important comment. We clarified the association between schizophrenia and violence in the revised manuscript as follows:

\- Patients with schizophrenia are involved in crime (mediated by substance use comorbidity) more so than is the general population \[9\]. (pg. 5, lines 114--116)

\- Incarceration accounts for about 1% of the direct non-healthcare costs. However, considering the severity of the matter, efforts to prevent violence that is associated with schizophrenia are needed. A meta-analysis \[9\] that investigated the association between schizophrenia and violence stated that substance abuse comorbidity mediates the association between schizophrenia and violence. Therefore, experts need to consider preventing substance abuse among patients with schizophrenia. (pg. 15, lines 278--284)

2\. In order to provide a more complete information to our readers on the topic, we would like to emphasize the importance to cross referencing very recent material on the same topic published in \"PLoS ONE \". Therefore, it would be highly appreciated if you would check the contents published in the last two years of \"PLoS ONE\" (<https://journals.plos.org/plosone/>) and add all material relevant to your article to the reference list.

� We went through recent materials related to our topic in PLoS One and added one relevant study to our reference list, which revealed that patients with schizophrenia have a high risk of acquiring physical diseases (e.g., cardiovascular disease):

\- \[10\] Cunningham R, Poppe K, Peterson D, Every-Palmer S, Soosay I, Jackson R. Prediction of cardiovascular disease risk among people with severe mental illness: a cohort study. PLoS One. 2019;14(9): e0221521.
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